LOS ANGELES & LONDON--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced the launch in the European Union of Abraxane® Paclitaxel 5 mg/ml powder for suspension for infusion. Abraxane® is an albumin-bound nanoparticle formulation of paclitaxel. In the EU, Abraxane® is indicated for the treatment of metastatic breast cancer in patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline-containing therapy is not indicated.
